Frontier Biotechnologies Company Description

Frontier Biotechnologies Inc., a commercial-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes various medicines that improve patients’ health in China.

It offers Aikening, a long-acting HIV fusion inhibitor for the treatment of HIV infection and AIDS. The company’s products under development include small RNA drugs, such as FB7011/FB7013/FB7014 to treat IgA nephropathy, FB7022/FB7021 for dyslipidemia, and FB7012/FB7041/FB7031/FB7032 for various other diseases, including hyperuricemia and gout, tumors, and metabolic-associated fatty liver diseases; FB4001, to treat patients with osteoporosis or high risk of fracture; and FB3002, for the treatment of pain in muscles, bones, and joints.

Frontier Biotechnologies Inc. was founded in 2002 and is headquartered in Nanjing, China.

Frontier Biotechnologies Inc.

Country	China
Founded	2002
Industry	Drug Manufacturers - Specialty & Generic
Sector	Healthcare
Employees	524
CEO	Dong Xie

Contact Details

Address: Building E-2, Green Window Nanjing, 211199 China
Phone	86 25 6964 8375
Website	frontierbiotech.com

Stock Details

Ticker Symbol	688221
Exchange	Shanghai Stock Exchange
Fiscal Year	January - December
Reporting Currency	CNY
SIC Code	2836

Key Executives

Name	Position
Dr. Dong Xie Ph.D.	Founder, Chairman, President and Chief Scientific Officer
Qi Shao	Senior Vice President, Chief Operating Officer and Chief Financial Officer
Dr. Rongjian Lu Ph.D.	Chief Technology Officer and Director
Hangzhou Lv	Senior Vice President of Marketing and Sales
Dr. Changjin Wang Ph.D.	MD, CBO and Director
Qianya Gao	Vice President, Deputy GM and Secretary of the Board of Directors
Xin Guan	Accounting Supervisor
Yuting Zhu	Supervisor and Deputy GM of Administration
Michael Hu	C.M.O.
Michael Wang	Senior Vice President and Head of Infectious Diseases Therapy Area